CTOs on the Move

Regency Hospital Company

www.regencyhospital.com

 
Regency Hospital Company, LLC is one of the leading companies in Healthcare, Pharmaceuticals, and Biotech industry. Regency Hospital Company, LLC is based in Alpharetta, GA. You can find more information on Regency Hospital Company, LLC at www.regencyhospital.com
  • Number of Employees: 1K-5K
  • Annual Revenue: $100-250 Million

Executives

Name Title Contact Details

Similar Companies

Field Safety Corp

Field Safety Corp is a Guilford, CT-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

SEIU UHW

SEIU-UHW is Working for a Healthy California Service Employees International Union-United Healthcare Workers West (SEIU-UHW) is a California union made up of 150,000 healthcare workers who work in hospitals, nursing homes, and in the community as home care providers. Our members are frontline caregivers, including respiratory care practitioners, dietary, environmental services and nursing staff who keep Californians healthy. We live and work throughout California: from the Bay Area to Sacramento and Los Angeles to the Central Valley. Our union of healthcare workers is driven to improve the healthcare system. Our mission is to provide quality care for all patients, expand access to excellent, affordable healthcare for all Californians and improve living standards for all workers.

Capital District Physicians` Health Plan

Founded in 1984 as a physician-founded and guided health plan, CDPHP and its affiliates currently serve members in 24 counties throughout New York with a full family of products.

Buxco Research Systems

Buxco Research Systems is a Wilmington, NC-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Telesta Therapeutics

Telesta Therapeutics is a biopharmaceutical company focused on the development, manufacturing and commercialization of transformative human therapeutics. Our main focus is on novel medicines that address major unmet medical needs, particularly in oncology. Our anchor product, MCNA, has completed a Phase III pivotal study in patients with non-muscle invasive bladder cancer that have failed the first line therapy, bacillus Calmette-Guérin (BCG). Telesta submitted a Biologics Licensing Application (BLA) for MCNA with the U.S. FDA on June 29, 2015 and is seeking, upon marketing approval in the U.S., to make MCNA available for patients and their physicians. Our ultimate goal is to transform the treatment landscape and prolong and improve the lives of those affected by bladder cancer, one of the most common types of cancers today.